Phaseline

Companies › Affibody

Affibody: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[177Lu]Lu-ABY-271
HER2-targeted Affibody fusion with lutetium-177 radioisotope
ERBB2Phase 1Metastatic Breast CancerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07081555[177Lu]Lu-ABY-271Phase 1Metastatic Breast CancerOncologyJan 2027

Targets

ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Jiangsu HengRui Medicine Shenyang Sunshine Pharmaceutical Suzhou Suncadia Biopharmaceuticals Pfizer Sichuan Baili Pharmaceutical Shanghai Henlius Biotech Chia Tai Tianqing Pharmaceutical Group Yuhan

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.